ℹ️ Compiled from public regulatory records · Last regulator revision: January 27, 2026🚩 Report this page
Pamabrom
Active ingredient
Sold as MIDOL BLOAT RELIEF
US FDACA Health Canada
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 2
- FDA reports (12 mo)
- 9
Overview
Pamabrom is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | January 27, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
1 product
Uses
Uses For the relief of temporary water weight gain bloating swelling full feeling associated with the premenstrual and menstrual periods.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Brands in Canada (1)
Sources & citations
- [1]FDA DailyMed · 186805ed-84fc-e7… · revised January 27, 2026 [PDF]
- [2]Health Canada (DPD) · 02527324 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.